文献速递神经介入DSA

ihtObtura:一种用于提高脑动静脉畸形治愈性栓塞效果的新型液体栓塞剂

ihtObtura, a New Liquid Embolic Agent for Improving Curative Embolization of Brain AVMs.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-11-03

该单中心首次人体研究对CLARIDAD试验进行事后分析,纳入42例脑动静脉畸形患者共102次栓塞手术,评估新型非黏附性液体栓塞剂ihtObtura的疗效与安全性。结果显示,完成全部治疗的患者中完全闭塞率为93%(26/28),整个队列为62%(26/42),所有患者均观察到栓塞材料逐渐失去不透X线性。

要点

  • ihtObtura是一种基于乙烯-乙烯醇共聚物的新型非黏附性液体栓塞剂,栓塞后逐渐失去不透X线性。
  • 完成全部治疗的患者6个月完全闭塞率为93%(26/28),整个队列为62%(26/42)。
  • 手术相关致残性永久神经功能缺损和手术相关死亡各1例,均与栓塞后颅内出血相关。

核心结论

  • ihtObtura具有与现有乙烯-乙烯醇共聚物基液体栓塞剂相似的性质,其主要创新为栓塞材料不透X线性逐渐降低,该特征可显著提高分期治疗中对残留畸形团成分的解剖理解,并初步提示可能提高完全闭塞率。

研究设计与样本

  • CLARIDAD试验的事后分析,为单中心首次人体研究,连续纳入2021年11月至2022年9月期间接受ihtObtura治疗的脑动静脉畸形患者42例,共102次栓塞手术。

关键影像表现/征象

  • 所有患者均观察到栓塞材料不透X线性逐渐降低。
  • 大多数患者表现为颅内出血(83%)。
  • 平均Spetzler-Martin分级为III-IV级(90%),平均畸形团大小为39 ± 14 mm。

诊断标准与关键数值

  • 完成全部治疗的患者中,6个月完全闭塞率为93%(26/28)。
  • 整个患者队列中,完全闭塞率为62%(26/42)。
  • 影像学终点包括6个月完全闭塞率和4-6周时不透X线性丧失。

临床应用与阅片要点

  • 栓塞后4-6周观察栓塞材料不透X线性丧失,有助于在分期治疗中区分残留畸形团成分。
  • 手术相关致残性永久神经功能缺损和手术相关死亡各1例,均与栓塞后颅内出血相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: We report our initial experience with ihtObtura, a novel nonadhesive liquid embolic agent (LEA) with progressive postembolization loss of radiopacity for curative embolization of brain AVMs (bAVMs).

MATERIALS AND METHODS: A post hoc analysis of the CLARIDAD trial, a single-center, first-in-human study, was performed. Collected data on consecutive patients with bAVMs treated with ihtObtura (between November 2021 and September 2022) were analyzed. Patient demographics, AVM characteristics, procedure details, and clinical treatment outcomes were collected. Imaging end points included complete occlusion rate at 6 months and loss of radiopacity at 4-6 weeks.

RESULTS: A total of 42 consecutive patients with bAVM who underwent 102 embolization procedures were included in the analysis. Most patients presented with intracranial hemorrhage (83%). The mean AVM classification was Spetzler-Martin (S-M) grade III-IV (90%), with a mean nidus size of 39 ± 14 mm. Complete occlusion was achieved in 26 of 28 patients (93%) who were able to complete all treatments during the study period. In the entire patient cohort, complete occlusion was observed in 62% (26/42 patients). Procedure-related disabling permanent neurologic deficit and procedure-related death were observed in 1 case each. Both events were related to postembolization intracranial hemorrhages. Progressive reduction of embolic material radiopacity was observed in all patients.

CONCLUSIONS: ihtObtura is a new LEA with similar properties as other currently available ethylene-vinyl alcohol copolymer (EVOH)-based liquid embolics with 1 major innovation-progressive reduction in embolic material radiopacity. This feature significantly improves anatomic understanding of residual AVM components during staged treatment of AVMs. This study provides initial evidence that the combination of EVOH-based diffusion properties with progressive loss of radiopacity allows for the potential improvement in rates of complete obliteration for bAVMs.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Llibre-Guerra JC, Siddiqui AH, Guimaraens L, et al. ihtObtura, a New Liquid Embolic Agent for Improving Curative Embolization of Brain AVMs. AJNR Am J Neuroradiol. 2025. PMID: 40360184. doi:10.3174/ajnr.A8834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。